271576-76-2

Upstream product

• 629621-85-8 1-{4-[5-(4-chloro-phenyl)-4-pyrimidin-4-yl-1-(toluene-4-sulfonyl)-1H-pyrazol-3-yl]-piperidin-1-yl}-ethanone 
• 503443-67-2 tert-butyl 4-{5-(4-chlorophenyl)-1-[(4-methylphenyl)sulfonyl]-4-pyrimidin-4-yl-1H-pyrazol-3-yl}piperidine-1-carboxylate 

Downstream Products

• 1228148-84-2 C₂₃H₂₆ClN₅O 
• 1228148-81-9 C₂₂H₂₆ClN₅O 
• 1228148-86-4 C₂₄H₂₃ClN₆ 
• 271576-80-8 2-{4-[3-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol 
• 1228148-82-0 C₂₂H₂₆ClN₅O 
• 1228148-89-7 C₂₁H₂₃ClN₆O 
• 1228148-88-6 C₂₁H₂₂ClN₅O₂ 
• 271576-77-3 SC 409 
• 1228148-80-8 C₂₀H₂₂ClN₅O 
• 635725-08-5 4-{3-(4-chlorophenyl)-5-[1-(4-fluorobenzyl)piperidin-4-yl]-1H-pyrazol-4-yl}pyrimidine hydrochloride 
• 635725-04-1 2-{4-[3-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}cyclopentanol fumarate 

Relevant academic research and scientific papers

Deprotection of N-Boc Groups under Continuous-Flow High-Temperature Conditions

The scope of thermolytic, N-Boc deprotection was studied on 26 compounds from the Pfizer compound library, representing a diverse set of structural moieties. Among these compounds, 12 substrates resulted in clean (≥95% product) deprotection, and an additional three compounds gave ≥90% product. The thermal de-Boc conditions were found to be compatible with a large number of functional groups. A combination of computational modeling, statistical analysis, and kinetic model fitting was used to support an initial, slow, and concerted proton transfer with release of isobutylene, followed by a rapid decarboxylation. A strong correlation was found to exist between the electrophilicity of the N-Boc carbonyl group and the reaction rate.

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase

Starting from an initial HTS screening lead, a novel series of C(5)-substituted diaryl pyrazoles were developed that showed potent inhibition of p38α kinase. Key to this outcome was the switch from a pyridyl to pyrimidine at the C(4)-position leading to analogs that were potent in human whole blood based cell assay as well as in a number of animal efficacy models for rheumatoid arthritis. Ultimately, we identified a clinical candidate from this substrate; SD-0006.

Process for making substituted pyrazoles

This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.